Savara Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew Pauls
- Full Time Employees
- 59
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building III Langhorne TX United States of America 78746
- IPO Date
- Apr 28, 2017
- CIK
- 0001160308
- Website
- savarapharma.com
- Similar Companies
- Business
- Savara Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for rare respiratory diseases. The company's primary product candidate is MOLBREEVI, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) delivered via the proprietary eFlow Nebulizer System licensed from PARI Pharma GmbH. MOLBREEVI is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, causing impaired gas exchange in the lungs. Savara focuses on developing innovative inhaled therapies that address significant unmet medical needs in rare respiratory conditions. Founded in 2007 and headquartered in Houston, Texas, Savara outsources much of its clinical development and manufacturing operations to specialized vendors and consultants, enabling capital-efficient development of its pipeline. Apart from MOLBREEVI, the company has historically focused on other product candidates like AeroVanc for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients, although MOLBREEVI remains its lead asset. Savara operates primarily in the United States and Europe, aligning its regulatory efforts with U.S. FDA, European Medicines Agency (EMA), and United Kingdom authorities. In the past two years, Savara has made significant strategic and operational advancements. Notably, it secured a European patent for its MOLBREEVI drug-device combination with PARI Pharma, protecting the proprietary nebulizer-based delivery system. The company plans regulatory submissions for MOLBREEVI’s biologics license application (BLA) re-submission in the U.S. and marketing authorization application (MAA) in Europe and the UK in early 2026. Recently, Savara completed a public offering with full exercise of the underwriters' option, raising approximately $149.5 million to support development and commercialization activities. Additionally, it negotiated a $75 million royalty funding agreement to support the potential launch of MOLBREEVI. Leadership enhancements have been made, including the promotion of Dr. Yasmine Wasfi to Chief Medical Officer, providing regulatory and clinical development expertise essential for navigating approval processes. Savara aims to become a leader in rare respiratory disease therapeutics by advancing innovative medicines targeted at orphan diseases like autoimmune pulmonary alveolar proteinosis, with an emphasis on leveraging inhalation delivery technologies. Its business model involves close collaboration with external specialized partners for manufacturing and clinical operations, focusing on efficient progression of its late-stage pipeline assets to commercialization. This comprehensive profile reflects Savara's current product offerings, operational focus, recent strategic financing, intellectual property developments, and leadership changes as of late 2025.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Announces New Employment Inducement Grant
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages
VR Adviser Adds Over 1 Million Savara Shares
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces Participation in 2026 Citizens Life Sciences Conference